Call for abstracts
- Abstracts submission opens 19 Dec 2023
- Abstracts submission closes 13 Feb 2024
- Abstracts evaluation notification 3 Apr 2024
Preparation of your abstract
- Abstracts must be submitted in English. A “blind” selection process will be used.
- No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
- The title should not be written entirely in capital letters.
- The size of the abstract is limited to 3,000 characters.
- The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
- Tables and figures (graphs) are allowed and they are not taken into consideration for the character count. On the other hand, pictures of patients and body parts are NOT allowed. Abstract containing pictures will be rejected.
- In order to be able to submit your abstract you must use the template downloadable on the submission platform.
- Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
- Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
- No mention of pharmaceutical company names should be included in the abstract.
The authors should specify if they prefer their submission to be considered for:
- e-Poster presentation only
- Oral presentation only
If you submit your abstract as “Oral presentation” and it does not get selected for one of the Free Communication sessions, you will still have the possibility to submit an e-poster (if the abstract is considered above the threshold of acceptance by the reviewers).
Evaluation and scoring
The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:
- Is the content interesting, informative, novel or important?
- Are the methods valid, the results relevant and the conclusions justified by the data?
- Is the data presented with clarity and with appropriate structure?
- Is the text written according to proper English grammar and syntactic style?
Copyright and publication of abstracts
Submission of an abstract implies that it has been approved by all listed authors.
The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation.
As part of the submission, the author grants EADV the exclusive right to first publish the abstract, and thereafter a non-exclusive right to publish, reproduce, distribute, display and store the abstract worldwide in all forms (including on the EADV website), formats and media now known or as developed in the future, including print, electronic and digital forms. For the avoidance of doubt, “electronic and digital forms” shall include but shall not be limited to databases, USB and forms accessible via electronic and digital networks, wireless transmission and communication systems. The author also grants EADV the exclusive right to retain income resulting from the above-mentioned publications by EADV. No fee shall be paid to the author by EADV for the license granted herein. The author will retain copyright of his or her abstract, including the pertaining moral rights. However, the author shall only reuse, reproduce or post the abstract with acknowledgment to the initial and first publication or presentation at an EADV event, and therefore reference the name of the EADV event and the date.
The License of Copyright Use between EADV and the author is governed and construed in accordance with the laws of Switzerland.
Accepted abstracts will be published here.